𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The use of recombinant factor VIII in the management of Hemophilia

✍ Scribed by Mannuccio Mannucci, Pier ;Gringeri, Alessandro

Book ID
105656378
Publisher
Springer-Verlag
Year
1991
Weight
420 KB
Volume
21
Category
Article
ISSN
0390-5748

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Influence of aggregation on immunogenici
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice
✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg

Mutations of the factor VIII gene in Tha
Mutations of the factor VIII gene in Thai hemophilia A patients
✍ V. Akkarapatumwong; S. Oranwiroon; P. Pung-amritt; A. Treesucon; P. Thanootaraku πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 121 KB πŸ‘ 2 views

Hemophilia A is a common X-linked bleeding disorder caused by mutations in the coagulation factor VIII gene. The entire coding and essential sequences of the factor VIII gene were generated by a combination of genomic DNA amplification and long reverse transcription-polymerase chain reaction (long R